ProMIS Neurosciences to Showcase Alzheimer’s Candidate at Key June Conferences
Event summary
- ProMIS Neurosciences will present at five conferences in June 2026, including Jefferies Global Healthcare Conference and Virtual Alzheimer’s R&D Day.
- CEO Neil Warma will discuss the company’s EpiSelect™ platform and lead Alzheimer’s candidate PMN310.
- Blinded 6-month interim data from the PRECISE-AD Phase 1b trial expected in early Q3 2026, with 12-month topline data anticipated in early 2027.
- PMN310 targets toxic amyloid-beta oligomers, avoiding plaque binding to potentially reduce off-target effects.
The big picture
ProMIS Neurosciences is positioning itself as a key player in the neurodegenerative disease space, with a focus on selective targeting of toxic misfolded proteins. The company’s upcoming conference appearances and anticipated trial data releases are critical for validating its approach against competitors in the Alzheimer’s disease market. Success in these areas could significantly enhance its valuation and strategic partnerships.
What we're watching
- Trial Timing
- Whether ProMIS can deliver on its timeline for reporting 6-month interim data in early Q3 2026 and 12-month topline data in early 2027.
- Investor Sentiment
- How investor reactions to the June conference presentations will impact ProMIS’s stock performance.
- Competitive Positioning
- The pace at which ProMIS can differentiate PMN310 in the crowded Alzheimer’s disease treatment landscape.
Related topics